Skip to main content
SpringerLink
Log in

Novartis update Exjade label

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Novartis.Important information about Exjade (Rm) (deferasirox) tablets for oral suspension. Internet Document: [3 pages], 12 Dec 2007. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Novartis update Exjade label. React. Wkly. 1183, 2 (2008). https://doi.org/10.2165/00128415-200811830-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200811830-00003

Keywords

Search

Navigation